Hot Features
プレミアム
IO Biotech Inc (IOBT)
NASDAQ
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced imm... IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. 詳細を表示
Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with...
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines...
-- Metastatic non-small cell lung cancer (NSCLC) patients treated in the first line setting with IO102-IO103 in combination with Keytruda® demonstrated promising activity with an overall response...
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines...
-- Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort -- -- No New Safety...
- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety...
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0729 | 9.59210526316 | 0.76 | 0.95 | 0.71 | 430768 | 0.84523206 | CS |
| 4 | -0.3172 | -27.5802104165 | 1.1501 | 1.29 | 0.66 | 760037 | 0.84048888 | CS |
| 12 | -0.077101 | -8.47262805206 | 0.910001 | 1.42 | 0.66 | 565702 | 0.94323702 | CS |
| 26 | -0.3671 | -30.5916666667 | 1.2 | 1.73 | 0.66 | 366872 | 1.0406879 | CS |
| 52 | -0.3871 | -31.7295081967 | 1.22 | 2.098 | 0.66 | 246247 | 1.17998077 | CS |
| 156 | -9.0071 | -91.5355691057 | 9.84 | 12.58 | 0.66 | 143561 | 2.12894698 | CS |
| 260 | -15.1671 | -94.794375 | 16 | 17.88 | 0.66 | 143852 | 2.40732714 | CS |
ZLAZARUS
1週前
ZLAZARUS
2週前
phrocks
2週前
ZLAZARUS
2週前
Rkrocks
2月前
Rkrocks
2月前
axelvento
2月前
Monksdream
2月前
glenn1919
2月前
axelvento
2月前
glenn1919
3月前
Monksdream
3月前
Monksdream
3月前
PonkenPlonken
4月前
PonkenPlonken
4月前
Monksdream
4月前
stock1ace1
5月前
Monksdream
5月前
ralfito
6月前
PonkenPlonken
6月前
PonkenPlonken
6月前
axelvento
6月前
axelvento
7月前
axelvento
7月前
axelvento
7月前
axelvento
8月前
axelvento
8月前
Monksdream
9月前
Monksdream
9月前
Monksdream
1年前
Monksdream
1年前
Monksdream
1年前
AJ Freely
1年前
The Night Stalker
1年前
kzivann
1年前
Phosphene
3年前
conix
3年前
Phosphene
3年前
Eggplant
3年前
Work Harder
3年前
Phosphene
3年前
Staypositive1
3年前
Phosphene
3年前
Phosphene
3年前
Phosphene
3年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
